Compugen to Present at Immunology 2014 Conference
29 Abril 2014 - 6:30AM
Business Wire
Compugen Ltd. (NASDAQ: CGEN) today announced that it will
present at the Immunology 2014 Conference to be held May 2-6 in
Pittsburgh. Immunology 2014, the annual meeting of the American
Association of Immunologists, is a premier international scientific
meeting at which world leaders in immunology present their
research. Compugen’s presentation will take place in a session
entitled “Harnessing Cellular and Molecular Interactions in
Autoimmunity” on Tuesday, May 6, 2014.
In her presentation, Iris Hecht, PhD, Principal Scientist
at Compugen, will review results for CGEN-15001, an Fc fusion
protein based on one of the immune checkpoint candidates discovered
by the Company. These results for CGEN-15001, obtained in in-vitro
systems and multiple models of autoimmune diseases, demonstrate
this product candidate’s efficacy and unique mode-of-action,
including promotion of regulatory T cells and its potential for
induction of long-term immune tolerance. Immune tolerance induction
is a highly sought-after approach for treatment of autoimmune
diseases, such as type 1 diabetes, rheumatoid arthritis and
multiple sclerosis.
The results being presented by Dr. Hecht include data from
Compugen’s long-standing collaboration with Stephen Miller, Judy
Gugenheim Research Professor of Microbiology-Immunology at
Northwestern University Feinberg School of Medicine. Compugen also
announced today that the scope of this collaboration has been
expanded to now include activities to further characterize the
immune function of a number of Compugen-discovered checkpoint
target candidates, in addition to further studies involving
CGEN-15001. The CGEN-15001 studies will address its potential for
ameliorating autoimmunity through the induction of immune
tolerance, and will include translational research using biological
samples from autoimmune patients.
Anat Cohen-Dayag, PhD, President and CEO of Compugen, stated,
“We are pleased to participate in this important conference to be
attended by world leading researchers in the field of immunology.
Our participation will take the form of both a poster and an oral
presentation reviewing the promising results for CGEN-15001, our
leading candidate for therapeutic use in immunology. Looking ahead,
we expect that the extended long-term collaboration with Professor
Miller and Northwestern University will further demonstrate the
unique therapeutic potential of this candidate for treatment of
multiple autoimmune diseases, as well as advance the research and
validation of a number of other Compugen discovered immune
checkpoint target candidates.”
The scientific poster accompanying Compugen’s Immunology 2014
Conference presentation will be available at the Company’s website
following the conference.
About Compugen
Compugen is a leading drug discovery company focused on
therapeutic proteins and monoclonal antibodies to address important
unmet needs in the fields of immunology and oncology. The Company
utilizes a broad and continuously growing integrated infrastructure
of proprietary scientific understandings and predictive platforms,
algorithms, machine learning systems and other computational
biology capabilities for the in silico (by computer) prediction and
selection of product candidates, which are then advanced in its
Pipeline Program. The Company's business model includes
collaborations covering the further development and
commercialization of product candidates at various stages from its
Pipeline Program and various forms of research and discovery
agreements, in both cases providing Compugen with potential
milestone payments and royalties on product sales or other forms of
revenue sharing. In 2012, Compugen established operations in
California for the development of oncology and immunology
monoclonal antibody therapeutic candidates against Compugen drug
targets.
Forward-looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements, which may include words such as “may,”
“expects,” “anticipates,” “potential,” “believes,” and “intends,”
and describe opinions about future events. Forward-looking
statements in this press release include, but are not limited to,
statements relating to CGEN-15001’s potential for ameliorating
autoimmunity through the induction of immune tolerance and for
treatment of multiple autoimmune diseases, that the planned
research activities under the expanded relationship with
Northwestern University Feinberg School of Medicine will be
undertaken or if undertaken will be successful, and the expected
advancement of the research for a number of other Compugen
discovered checkpoint target candidates. These forward-looking
statements involve known and unknown risks and uncertainties that
may cause the actual results, performance or achievements of
Compugen to be materially different from any future results,
performance or achievements expressed or implied by such
forward-looking statements. Some of these risks and other factors
are discussed in the "Risk Factors" section of Compugen’s Annual
Report on Form 20-F for the year ended December 31, 2013 as filed
with the Securities and Exchange Commission. In addition, any
forward-looking statements represent Compugen’s views only as of
the date of this release and should not be relied upon as
representing its views as of any subsequent date. Compugen does not
assume any obligation to update any forward-looking statements
unless required by law.
Compugen Ltd.Tsipi HaitovskyGlobal Media
Liaison+972-52-598-9892tsipih@netvision.net.il
Compugen (NASDAQ:CGEN)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Compugen (NASDAQ:CGEN)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024